Tasso 40 mg (Tablet)

Unit Price: ৳ 290.00 (1 x 30: ৳ 8,700.00)
Strip Price: ৳ 8,700.00

Medicine Details

Category Details
Generic Osimertinib
Company Jenphar bangladesh ltd
Also available as
Tasso 80 mg tablet

Title

  • Tasso

Categories

  • Medicine
  • Cancer Treatment
  • Pharmaceuticals
  • Healthcare

Description

  • Indicated for first-line treatment of metastatic non-small cell lung cancer
  • Kinase inhibitor of epidermal growth factor receptor (EGFR)
  • Recommended dosage: 80 mg tablet once a day
  • Can cause fetal harm when administered to a pregnant woman
  • Storage: Store below 30°C, protect from moisture & light

Color Options

  • NA

Dimensions

  • NA

Functions

  • First-line treatment of metastatic non-small cell lung cancer
  • Kinase inhibitor of EGFR
  • Treatment of patients with metastatic EGFR T790M mutation-positive NSCLC
  • Can cause fetal harm
  • Diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue, decreased appetite (common side effects)

Materials

  • Osimertinib

Technical Specifications

  • Binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion)
  • Exhibits anti-tumor activity against NSCLC lines harboring EGFR-mutations

Design Elements

  • Tablet form
  • Dispersible tablet
  • Oral administration
  • Pharmacologically-active metabolites (AZ7550 and AZ5104)
  • Linear pharmacokinetics (PK)

Usability Features

  • Can be taken with or without food
  • Recommended to be taken with non-carbonated water
  • Can be administered via nasogastric tube if required

Dosage & Administration

  • Recommended dose: 80 mg tablet once a day
  • Can be taken with or without food
  • Tablet should be dispersed in 60 ml of non-carbonated water and swallowed immediately
  • Do not crush, heat, or ultrasonicate the tablet during preparation
  • Dispersed tablet should be administered via nasogastric tube if required

Interactions

  • Avoid concomitant administration with strong CYP3A inhibitors
  • Avoid concomitant administration with strong CYP3A inducers
  • Effect on other drugs: Avoid concomitant administration with drugs that are sensitive substrates of CYP3A, BCRP, or CYP1A2

Side Effects

  • Common adverse reactions: diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue, decreased appetite

Pregnancy & Lactation

  • Can cause fetal harm
  • Advise females of reproductive potential to use effective contraception during treatment and for 6 weeks after the final dose
  • Advise male patients with female partners of reproductive potential to use effective contraception during and for 4 months following the final dose

Precautions & Warnings

  • Interstitial Lung Disease (ILD)/Pneumonitis occurred in 3.9% of the patients
  • QTc Interval Prolongation: Monitor electrocardiograms and electrolytes
  • Cardiomyopathy occurred in 1.4% of patients
  • Embryo-Fetal Toxicity: Advise effective contraception during treatment

Use in Special Populations

  • No clinically significant differences based on age, sex, ethnicity, renal impairment, or hepatic impairment
  • No established safety and effectiveness in pediatric patients
  • No overall differences in effectiveness based on age
  • No dose adjustment recommended in patients with mild, moderate, or severe renal impairment

Therapeutic Class

  • Cytotoxic Chemotherapy

Storage Conditions

  • Store below 30°C
  • Protect from moisture & light
  • Safely dispose of expired or unneeded medicine
  • Keep out of reach of children

Related Brands